Barclays’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-2,500
| Closed | -$44K | – | 5379 |
|
|
2020
Q4 | $44K | Hold |
2,500
| – | – | ﹤0.01% | 4468 |
|
|
2020
Q3 | $29K | Hold |
2,500
| – | – | ﹤0.01% | 4824 |
|
|
2020
Q2 | $33K | Buy |
+2,500
| New | +$30K | ﹤0.01% | 5084 |
|
|
2019
Q4 | – | Sell |
-13,875
| Closed | -$231K | – | 7073 |
|
|
2019
Q3 | $231K | Sell |
13,875
-91,512
| -87% | -$1.27M | ﹤0.01% | 4863 |
|
|
2019
Q2 | $1.45M | Buy |
105,387
+95,239
| +939% | +$1.46M | ﹤0.01% | 3287 |
|
|
2019
Q1 | $175K | Buy |
10,148
+8,239
| +432% | +$130K | ﹤0.01% | 4923 |
|
|
2018
Q4 | $24K | Sell |
1,909
-8,920
| -82% | -$135K | ﹤0.01% | 5824 |
|
|
2018
Q3 | $175K | Buy |
10,829
+7,651
| +241% | +$109K | ﹤0.01% | 5113 |
|
|
2018
Q2 | $41K | Sell |
3,178
-2,097
| -40% | -$28.3K | ﹤0.01% | 5766 |
|
|
2018
Q1 | $65K | Buy |
5,275
+1,259
| +31% | +$15.3K | ﹤0.01% | 5693 |
|
|
2017
Q4 | $56K | Buy |
4,016
+3,492
| +666% | +$51.2K | ﹤0.01% | 5688 |
|
|
2017
Q3 | $9K | Sell |
524
-1,395
| -73% | -$22.7K | ﹤0.01% | 6207 |
|
|
2017
Q2 | $32K | Buy |
1,919
+1,383
| +258% | +$20.7K | ﹤0.01% | 5584 |
|
|
2017
Q1 | $9K | Buy |
536
+419
| +358% | +$5.98K | ﹤0.01% | 6123 |
|
|
2016
Q4 | $2K | Sell |
117
-159
| -58% | -$2.23K | ﹤0.01% | 6407 |
|
|
2016
Q3 | $3K | Buy |
+276
| New | +$2.77K | ﹤0.01% | 6180 |
|
|
2016
Q2 | – | Sell |
-900
| Closed | -$8K | – | 6767 |
|
|
2016
Q1 | $8K | Buy |
+900
| New | +$9.23K | ﹤0.01% | 5552 |
|
|
2015
Q4 | – | Sell |
-105
| Closed | -$1K | – | 6820 |
|
|
2015
Q3 | $1K | Sell |
105
-280
| -73% | -$3.79K | ﹤0.01% | 6665 |
|
|
2015
Q2 | $5K | Sell |
385
-112
| -23% | -$1.51K | ﹤0.01% | 6492 |
|
|
2015
Q1 | $7K | Sell |
497
-244
| -33% | -$3.32K | ﹤0.01% | 6468 |
|
|
2014
Q4 | $10K | Buy |
741
+314
| +74% | +$4.29K | ﹤0.01% | 6734 |
|
|
2014
Q3 | $6K | Buy |
427
+181
| +74% | +$2.77K | ﹤0.01% | 7138 |
|
|
2014
Q2 | $4K | Sell |
246
-1,815
| -88% | -$32.7K | ﹤0.01% | 7224 |
|
|
2014
Q1 | $41K | Buy |
2,061
+1,962
| +1,982% | +$42.4K | ﹤0.01% | 6159 |
|
|
2013
Q4 | $2K | Buy |
+99
| New | +$1.75K | ﹤0.01% | 7388 |
|
Barclays's OXFD Position: Q1 2021 in Review
Barclays sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 2,500 shares — an estimated $44K sold.
Barclays first reported a position in OXFD in Q4 2013 and held it in 25 quarters. The position peaked at $1.45M in Q2 2019. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.
- Barclays reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
- Barclays sold 2,500 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $44K.
- Barclays first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2013 and held it in 25 quarters.
- Barclays's Oxford Immunotec Global PLC Ordinary Shares position peaked at $1.45M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.
Based on Barclays's 13F filing for Q1 2021, filed 13 May 2021.